Predictors for Progression of Atrial Fibrillation in Patients Awaiting Atrial Fibrillation Ablation

Canadian Journal of Cardiology

Volumn 32, Issue 11, 2016, Pages 1348-1354

  Kochhäuser, Simon ^a,b   Dechering, Dirk G ^b   Trought, Kathleen ^a   Hache, Philip ^a   Haig Carter, Tanjah ^a   Khaykin, Yaariv ^a   Wulffhart, Zaev ^a   Pantano, Alfredo ^a   Tsang, Bernice ^a   Eckardt, Lars ^b   Verma, Atul ^a  

^a SOUTHLAKE REGIONAL HEALTH CENTRE   (Canada)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; DOFETILIDE; DRONEDARONE; PROPAFENONE; SOTALOL;

ADULT; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR RISK; CATHETER ABLATION; CONTROLLED STUDY; DISEASE COURSE; ELECTROCARDIOGRAM; FEMALE; HOLTER MONITORING; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PAROXYSMAL ATRIAL FIBRILLATION; RADIOFREQUENCY ABLATION; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SELF REPORT; DIAGNOSTIC IMAGING; HEART ATRIUM; HEART FAILURE; MULTIVARIATE ANALYSIS; OPERATION DURATION; PREDICTIVE VALUE; RECURRENT DISEASE; RISK ASSESSMENT;

ATRIAL FIBRILLATION; CATHETER ABLATION; DISEASE PROGRESSION; FEMALE; HEART ATRIA; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OPERATIVE TIME; PREDICTIVE VALUE OF TESTS; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 84964618107     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2016.02.031     Document Type: Article

References (16)

1. 1 Wilke, T., Groth, A., Mueller, S., et al. Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Europace 15 (2013), 486–493.
2. 2 Kerr, C.R., Humphries, K.H., Talajic, M., et al. Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. Am Heart J 149 (2005), 489–496.
3. 3 Verma, A., Cairns, J.A., Mitchell, L.B., et al. 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol 30 (2014), 1114–1130.
4. 4 Morillo, C.A., Verma, A., Connolly, S.J., et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. JAMA 311 (2014), 692–700.
5. 5 Calkins, H., Reynolds, M.R., Spector, P., et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol 2 (2009), 349–361.
6. 6 Cappato, R., Calkins, H., Chen, S.A., et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 3 (2010), 32–38.
7. 7 de Vos, C.B., Pisters, R., Nieuwlaat, R., et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol 55 (2010), 725–731.
8. 8 Lang, R.M., Bierig, M., Devereux, R.B., et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18 (2005), 1440–1463.
9. 9 Verma, A., Jiang, C.Y., Betts, T.R., et al. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med 372 (2015), 1812–1822.
10. 10 Nieuwlaat, R., Capucci, A., Camm, A.J., et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 26 (2005), 2422–2434.
11. 11 Barrett, T.W., Self, W.H., Wasserman, B.S., McNaughton, C.D., Darbar, D., Evaluating the HATCH score for predicting progression to sustained atrial fibrillation in ED patients with new atrial fibrillation. Am J Emerg Med 31 (2013), 792–797.
12. 12 De Vos, C.B., Breithardt, G., Camm, A.J., et al. Progression of atrial fibrillation in the REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation cohort: clinical correlates and the effect of rhythm-control therapy. Am Heart J 163 (2012), 887–893.
13. 13 Le Heuzey, J.Y., Breithardt, G., Camm, J., et al. The RecordAF study: design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation. Am J Cardiol 105 (2010), 687–693.
14. 14 Burstein, B., Nattel, S., Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 51 (2008), 802–809.
15. 15 Yoon, Y.E., Oh, I.Y., Kim, S.A., et al. Echocardiographic Predictors of Progression to Persistent or Permanent Atrial Fibrillation in Patients with Paroxysmal Atrial Fibrillation (E6P Study). J Am Soc Echocardiogr 28 (2015), 709–717.
16. 16 Suzuki, T., Yamazaki, T., Ogawa, S., Nagai, R., Yamashita, T., Echocardiographic predictors of frequency of paroxysmal atrial fibrillation (AF) and its progression to persistent AF in hypertensive patients with paroxysmal AF: results from the Japanese Rhythm Management Trial II for Atrial Fibrillation (J-RHYTHM II Study). Heart Rhythm 8 (2011), 1831–1836.